Basic Information
| ID | DRAMP20912 |
|---|
| Sequence | FLGGLIKKWPWWPWRR |
|---|
| Length | 16 |
|---|
| Name | RN7-IN9(designed based on indolicidin and ranalexin) |
|---|
| Source | Synthetic construct |
|---|
| Activity | Antimicrobial, Antibacterial, Anti-Gram+, Anti-Gram- |
|---|
| Pathogen | [Ref.26046345] Gram-negative bacteria: Escherichia coli ATCC 25922(MIC=7.81μg/ml), Pseudomonas aeruginosa ATCC 15442(MIC=31.25μg/ml), Acinetobacter baumanii ATCC 15308(MIC=31.25μg/ml), citrobacter spp(MIC>250μg/ml), Klebsiella pneumoniae(MIC>250μg/ml) ;## Gram-positive bacteria: Streptococcus pneumoniae(30 clinical isolates)(MIC=7.81–15.62μg/ml), Staphylococcus aureus ATCC 25923(MIC=7.81μg/ml), Methicillin resistant Staphylococcus aureus (MRSA)(MIC=7.81μg/ml), Enterococcus cloacae(MIC>250μg/ml), |
|---|
| Hemolytic Activity | [Ref.26046345] The hemolytic activities of RN7-IN7 is 0.0% at 15.62μg/ml against human RBCs. |
|---|
| Cytotoxicity | [Ref.26046345] The cell viability of NL-20 cell line is not affected (<10%) below 31.25 μg/ml. The cell viability of NL-20 is 51%, 13% and 7% at peptide concentrations of 62.5, 125 and 250 μg/ml.## The cell viability of WRL-68 cell line is not affected |
|---|
| N-terminal Modification | Free |
|---|
| C-terminal Modification | Amidation |
|---|
| Linear/Cyclic/Branched | Linear |
|---|
| Uniprot |
|
|---|
| PDB |
|
|---|
| 3D View | |
|---|
| PDB Download | Download PDB Predicted by Alphafold2 |
|---|
| PubMed ID | 26046345 |
|---|
